A clinical trial on MUSUMUSKKAI KUDINEER in the management of PITHA PAANDU (IRON DEFICIENCY ANAEMIA)

A Prospective Open labelled non randomized phase II clinical trial on MUSUMUSKKAI KUDINEER in the management of PITHA PAANDU (IRON DEFICIENCY ANAEMIA)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040037

Enrollment

Registered

2022-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: MUSUMUSKKAI KUDINEER: 30-60 ml Twice a day (orally) Control Intervention1: NIL: 0

Eligibility

Inclusion criteria

Inclusion criteria: 1.Hb level above 7.0 grams - below 10 grams 2.Patient with the symptoms of Pallor of skin, Mucous membrane, Conjunctiva, Nail beds. Fatigue, shortness of breath, palpitation. Worm infestations. Blood loss due to Menstrual disorders, Hemorrhoids, and Peptic ulcer 3.Clinically diagnosis in Iron Deficiency Anaemia, smear showing hypochromic microcytic anaemia

Exclusion criteria

Exclusion criteria: 1.Hb levels below 7.0 grams and above 10 grams 2.Congenital heart diseases 3.Patients with chronic renal diseases 4.Liver diseases 5.Inherited hemolytic defects 6.Thalassemia 7.Thyroid disorder 8.Diabetes mellitus 9.Pregnancy and lactating mother

Design outcomes

Primary

Measure	Time frame
To evaluate the therapeutic efficacy of clinical trial drug in management of Pitha PaanduTimepoint: 45 days	—

Secondary

Measure	Time frame
1.To evaluate the biochemical physico-chemical and phytochemical analysis of clinical trial drug 2.To evaluate the antimicrobial activity of trial drug 3.To evaluate the safety profile for acute and subacute toxicity of the trial drug musumuskkai kudineer 4.To evaluate pharmacological analysis of the clinical trial drug 5.To evaluate Siddha parameters and modern parameters during the treatment of Pitha Paandu with trial drug 6.To evaluate the statistical analysis of the clinical trial drug musumuskkai kudineerTimepoint: 45 days	—

Measure

Time frame

1.To evaluate the biochemical physico-chemical and phytochemical analysis of clinical trial drug 2.To evaluate the antimicrobial activity of trial drug 3.To evaluate the safety profile for acute and subacute toxicity of the trial drug musumuskkai kudineer 4.To evaluate pharmacological analysis of the clinical trial drug 5.To evaluate Siddha parameters and modern parameters during the treatment of Pitha Paandu with trial drug 6.To evaluate the statistical analysis of the clinical trial drug musumuskkai kudineerTimepoint: 45 days

—

Countries

India

Contacts

Public ContactProf Dr A Manoharan MDs PhD

Government Siddha Medical College and Hospital

siddhadrgs21@gmail.com9443358271

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026